Indianapolis, Indiana, United States The leading representative office of defined VC is situated in the Indianapolis. The fund was located in North America if to be more exact in United States. Lilly Ventures appeared to be a CVC structure as part of the corporation.
This organization was formed by Ron Laufer. We also calculated 2 valuable employees in our database.
Among the most successful fund investment fields, there are Pharmaceutical, Therapeutics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 4 of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Receptos, Viracta Therapeutics, Serenex.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Lilly Ventures, startups are often financed by Polaris Partners, SV Health Investors, Atlas Venture. The meaningful sponsors for the fund in investment in the same round are SR One, Polaris Partners, Atlas Venture. In the next rounds fund is usually obtained by Novartis Venture Fund, Venrock, SR One.
The fund is constantly included in 2-6 deals per year. The real fund results show that this VC is 8 percentage points more often commits exit comparing to other companies. The increased amount of exits for fund were in 2018. The high activity for fund was in 2009. The usual things for fund are deals in the range of 10 - 50 millions dollars. Opposing the other organizations, this Lilly Ventures works on 2 percentage points more the average amount of lead investments.
Related Funds
| Fund Name | Location |
| 9Point8 Capital | New York, New York, United States |
| AGA Tech Invest LLC | - |
| Asia Global Crossing | - |
| Business Angels Club Aargau | Aargau, Brugg, Switzerland |
| CIT Bank | Salt Lake City, United States, Utah |
| Guizhou Kefengtou | China, Guizhou, Liaoning |
| Investopad | Gurgaon, Haryana, India |
| Koito | Chiyoda, Japan |
| Link-U | Japan, Tokyo |
| Mammoth with ThinkHR | - |
| peiker Consumer Electronics Evolution GmbH | - |
| R-Cubed Capital Partners | - |
| Shanghai Junbao Investment Management | China, Shanghai |
| Shenzhen AVIC Kaisheng Auto Semiconductor Investment | China, Guangdong, Shenzhen |
| Slack Fund | California, Daly City, United States |
| TrentoRISE | Italy, Trentino-Alto Adige, Trento |
| Tsuzuki Denki | Akiruno, Japan |
| University of New Brunswick | Canada, Fredericton, New Brunswick |
| Zhenghan Investment | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
IpiNovyx Bio | $10M | 05 Oct 2021 | New York, New York, United States | ||
Kymera Therapeutics | $65M | 13 Nov 2018 | Cambridge, Massachusetts, United States | ||
Nimbus Therapeutics | $65M | 05 Jun 2018 | Cambridge, Massachusetts, United States | ||
Kymera Therapeutics | $30M | 30 Oct 2017 | Cambridge, Massachusetts, United States | ||
Cavion | $26M | 06 Jan 2017 | Virginia, United States | ||
Symic Biomedical | $25M | 01 Dec 2015 | California, United States | ||
Aeglea BioTherapeutics | $44M | 23 Mar 2015 | Austin, Texas, United States | ||
Nimbus Therapeutics | $43M | 19 Mar 2015 | Cambridge, Massachusetts, United States | ||
Lysosomal Therapeutics | $20M | 03 Feb 2015 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
IpiNovyx Bio | $10M | 05 Oct 2021 | New York, New York, United States | ||
Kymera Therapeutics | $65M | 13 Nov 2018 | Cambridge, Massachusetts, United States | ||
Nimbus Therapeutics | $65M | 05 Jun 2018 | Cambridge, Massachusetts, United States | ||
Kymera Therapeutics | $30M | 30 Oct 2017 | Cambridge, Massachusetts, United States | ||
Cavion | $26M | 06 Jan 2017 | Virginia, United States | ||
Symic Biomedical | $25M | 01 Dec 2015 | California, United States | ||
Aeglea BioTherapeutics | $44M | 23 Mar 2015 | Austin, Texas, United States | ||
Nimbus Therapeutics | $43M | 19 Mar 2015 | Cambridge, Massachusetts, United States | ||
Lysosomal Therapeutics | $20M | 03 Feb 2015 | Cambridge, Massachusetts, United States |
